Dengue subunit vaccine - Merck Sharp and DohmeAlternative Names: DEN 1 80E; Dengue subunit vaccine - Hawaii Biotech; HB6; HBV-001 D1; Tetravalent dengue vaccine - Merck Sharp & Dohme; V 180
Latest Information Update: 28 Dec 2015
At a glance
- Originator Hawaii Biotech
- Developer Merck Sharp & Dohme; National Institute of Allergy and Infectious Diseases
- Class Dengue vaccines; Subunit vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase I Dengue